Review article: natural history and prognostic prediction of patients with hepatocellular carcinoma.

Abstract:

:The knowledge of the natural history of patients with hepatocellular carcinoma is important to estimate the prognosis at diagnosis and indicate the best therapy. Prognosis is related to tumour stage at diagnosis, degree of liver function impairment induced either by the tumour itself or by the underlying cirrhosis, general physical condition of the patients, and potential impact of therapy. Prognostic estimation should take into account all four aspects. Treatment is very relevant to be considered in patients with early stage tumours since surgical resection, transplantation or percutaneous ablation provide a high rate of complete responses and thus, improve survival. This might be as high as 50-75% at 5 years. Patients diagnosed at an intermediate/advanced stage will receive palliative treatment and prospective studies have recently redefined the outcome predictors of this stratum. Asymptomatic patients in whom the tumour has not invaded vessels or disseminated may reach a 50% survival at 3 years, while those with adverse predictors do not reach this time point. These data have to be taken into account not only in the conventional clinical practice, but also in the design and evaluation of prospective investigations that should be properly powered to reach an informative sample size. To achieve both aims, within the Barcelona Clinic Liver Cancer Group we have developed a staging system that combines prognosis prediction with decision making, thus becoming a useful tool both for practice and research.

journal_name

Aliment Pharmacol Ther

authors

Varela M,Sala M,Llovet JM,Bruix J

doi

10.1046/j.1365-2036.17.s2.11.x

subject

Has Abstract

pub_date

2003-06-01 00:00:00

pages

98-102

eissn

0269-2813

issn

1365-2036

pii

1625

journal_volume

17 Suppl 2

pub_type

杂志文章,评审
  • Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open.

    abstract:BACKGROUND:For patients with UC, flexible maintenance dosing therapy may confer advantages for safety, efficacy, costs and patient preference. Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of UC. AIM:To assess the efficacy and safety of tofacitinib dose de-escalation and escalation in patients...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/apt.15555

    authors: Sands BE,Armuzzi A,Marshall JK,Lindsay JO,Sandborn WJ,Danese S,Panés J,Bressler B,Colombel JF,Lawendy N,Maller E,Zhang H,Chan G,Salese L,Tsilkos K,Marren A,Su C

    更新日期:2020-01-01 00:00:00

  • The effects of flumazenil on alertness and hypoxia in elderly patients after ERCP.

    abstract::It is not known whether hypoxia, associated with upper gastrointestinal endoscopic procedures when midazolam sedation is used without narcotics, persists into the post-procedure recovery period. Thirty consecutive patients aged over 60 years, undergoing ERCP using midazolam sedation alone, were monitored clinically an...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1992.tb00739.x

    authors: Haines DJ,Bibbey D,Green JR

    更新日期:1992-12-01 00:00:00

  • Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions.

    abstract:AIM:To appraise the tolerance and efficacy of an induction of tolerance protocol to infliximab permitting the re-administration of the drug to patients with Crohn's disease having had infusion reactions requiring suspension of treatment. METHODS:Fourteen patients were included in the induction of tolerance protocol. E...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2006.03026.x

    authors: Duburque C,Lelong J,Iacob R,Seddik M,Desreumaux P,Fournier C,Wallaert B,Cortot A,Colombel JF

    更新日期:2006-09-01 00:00:00

  • Review article: the potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection.

    abstract:BACKGROUND:A short-term course of pegylated-interferon (Peg-IFN), or a long-term treatment with a third generation nucleot(s)ide analogue (NUC), of chronic hepatitis B (CHB) infection achieves viral suppression and may prevent disease progression. Owing to different mechanisms of action of the two regimens, a Peg-IFN a...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/apt.13751

    authors: Viganò M,Invernizzi F,Grossi G,Lampertico P

    更新日期:2016-10-01 00:00:00

  • Metabolic adaptation of colonic microbiota to galactooligosaccharides: a proof-of-concept-study.

    abstract:BACKGROUND:Prebiotics have been shown to reduce abdominal symptoms in patients with functional gut disorders, despite that they are fermented by colonic bacteria and may induce gas-related symptoms. AIM:To investigate changes in the metabolic activity of gut microbiota induced by a recognised prebiotic. METHODS:Healt...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13931

    authors: Mego M,Manichanh C,Accarino A,Campos D,Pozuelo M,Varela E,Vulevic J,Tzortzis G,Gibson G,Guarner F,Azpiroz F

    更新日期:2017-03-01 00:00:00

  • Azathioprine and mercaptopurine in the management of patients with chronic, active microscopic colitis.

    abstract:BACKGROUND:Microscopic colitis (MC) is a common chronic diarrhoeal disease, and remission can be induced with budesonide. However, diarrhoea relapses frequently when budesonide is tapered and a few patients become budesonide intolerant. AIM:To examine retrospectively the effect of azathioprine (AZA) and mercaptopurine...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/apt.12261

    authors: Münch A,Fernandez-Banares F,Munck LK

    更新日期:2013-04-01 00:00:00

  • Susceptibility loci reported in genome-wide association studies are associated with Crohn's disease in Canadian children.

    abstract:BACKGROUND:Recent genome-wide association studies based on adult and paediatric populations have implicated >30 genes/loci as susceptibility loci for Crohn's disease (CD). AIMS:To investigate whether reported genes/loci were also associated with CD in Canadian children. DESIGN AND METHODS:A case-control design was im...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1365-2036.2010.04294.x

    authors: Amre DK,Mack DR,Morgan K,Israel D,Deslandres C,Seidman EG,Lambrette P,Costea I,Krupoves A,Fegury H,Dong J,Grimard G,Levy E

    更新日期:2010-06-01 00:00:00

  • Do mucosal defensive agents improve the cure rate when used with dual or triple therapy regimens for eradicating Helicobacter pylori infection?

    abstract:BACKGROUND:Some of mucosal defensive agents have anti-Helicobacter pylori activities. However, their effectiveness in eradicating H. pylori infection has not been evaluated. AIM:To assess the additive effect of mucosal defensive agents in eradication regimens using statistical analysis. METHODS:Pertinent studies were...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1046/j.1365-2036.2000.00692.x

    authors: Hojo M,Miwa H,Kikuchi S,Sato N

    更新日期:2000-02-01 00:00:00

  • The effect of omeprazole on gastric juice viscosity, pH and bacterial counts.

    abstract:BACKGROUND:In vitro studies have shown that pH is an important determinant of mucus structure and function, but the relationship in vivo is unclear. Omeprazole increases intragastric pH and also allows bacterial overgrowth. In this study we have assessed the effect of omeprazole on gastric juice viscosity and examined ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.1996.tb00183.x

    authors: Goddard AF,Spiller RC

    更新日期:1996-02-01 00:00:00

  • The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up.

    abstract:BACKGROUND:Anti-TNF agents are now widely used in Crohn's disease (CD), and in ulcerative colitis (UC). AIM:To review the safety profile of anti-TNF agents in all patients treated with infliximab in Edinburgh from 1999 to 2007. METHODS:Complete data were available on 202/207 patients comprising 157 CD, 42 UC and thre...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2008.03882.x

    authors: Lees CW,Ali AI,Thompson AI,Ho GT,Forsythe RO,Marquez L,Cochrane CJ,Aitken S,Fennell J,Rogers P,Shand AG,Penman ID,Palmer KR,Wilson DC,Arnott ID,Satsangi J

    更新日期:2009-02-01 00:00:00

  • Prevalence of coeliac disease in Northwest China: heterogeneity across Northern Silk road ethnic populations.

    abstract:BACKGROUND:Epidemiological data of coeliac disease are lacking from the central Asian region. AIMS:To verify the occurrence of coeliac disease amongst four major ethnic groups of Xinjiang Uyghur Autonomus Region, China. METHODS:2277 in-patients with gastrointestinal symptoms (1391 Han, 608 Uyghur, 146 Kazakh and 132 ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.15737

    authors: Zhou C,Gao F,Gao J,Yuan J,Lu J,Sun Z,Xu M,Engel J,Hui W,Gilissen L,Chen H

    更新日期:2020-06-01 00:00:00

  • Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation -- a placebo-controlled study.

    abstract:BACKGROUND:Mesalazine suppositories are recommended and widely used as the standard therapy in induction and maintenance of remission for proctitis. AIM:To evaluate the efficacy of mesalazine suppositories in patients with ulcerative colitis (UC) and rectal inflammation; and in patient groups categorised by the extent...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/apt.12362

    authors: Watanabe M,Nishino H,Sameshima Y,Ota A,Nakamura S,Hibi T

    更新日期:2013-08-01 00:00:00

  • Flumecinol for the treatment of pruritus associated with primary biliary cirrhosis.

    abstract:OBJECTIVE:To determine whether flumecinol (3-trifluoromethyl-alpha-ethylbenzhydrol, Zixoryn) is effective in ameliorating pruritus of cholestasis, particularly in primary bilary cirrhosis. METHODS AND RESULTS:50 patients (46 with primary biliary cirrhosis, PBC) took oral flumecinol 600 mg or identical placebo once wee...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1994.tb00297.x

    authors: Turner IB,Rawlins MD,Wood P,James OF

    更新日期:1994-06-01 00:00:00

  • Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects.

    abstract:AIM:To compare the antisecretory effects of rabeprazole and esomeprazole in an open, randomized, two-way crossover, clinical pharmacology study. METHODS:Twenty-four healthy subjects (14 men, 10 women; mean age 26.8 years) received rabeprazole 20 mg or esomeprazole 20 mg daily on days 1-5, with a 14-day 'wash-out'. Int...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.2002.01292.x

    authors: Warrington S,Baisley K,Boyce M,Tejura B,Morocutti A,Miller N

    更新日期:2002-07-01 00:00:00

  • Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases.

    abstract:BACKGROUND:Historically, the beneficial effects of the nonsystemic oral agent rifaximin on various gastrointestinal (GI) disorders have been attributed to direct antibiotic activity on gut microbiota. However, data are accumulating to suggest that other nonantibacterial effects may be involved in rifaximin efficacy. A...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type:

    doi:10.1111/apt.13406

    authors: DuPont HL

    更新日期:2016-01-01 00:00:00

  • Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole.

    abstract:BACKGROUND:Studies to date have not directly compared the pharmacodynamic efficacies of different proton pump inhibitors in controlling intragastric acidity in patients treated with non-steroidal anti-inflammatory drugs. AIM:To compare acid suppression with once-daily esomeprazole 40 mg, lansoprazole 30 mg and pantopr...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2036.2006.02867.x

    authors: Goldstein JL,Miner PB Jr,Schlesinger PK,Liu S,Silberg DG

    更新日期:2006-04-15 00:00:00

  • Renal function and cardiovascular risk profile after conversion from ciclosporin to tacrolimus: prospective study in 80 liver transplant recipients.

    abstract:BACKGROUND:Increased risk of cardiovascular and cerebrovascular disease in liver transplant recipients results in particular from the side effects of calcineurin inhibitor-based immunosuppressive therapy. Several studies have demonstrated a more favourable outcome for patients receiving tacrolimus (TAC) as compared wit...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2009.04099.x

    authors: Beckebaum S,Klein C,Varghese J,Sotiropoulos GC,Saner F,Schmitz K,Gerken G,Paul A,Cicinnati VR

    更新日期:2009-10-15 00:00:00

  • Randomized, multicentre comparison of sodium alginate and cisapride in the symptomatic treatment of uncomplicated gastro-oesophageal reflux.

    abstract:AIM:To assess the efficacy and tolerance of sodium alginate compared to cisapride in patients suffering from reflux symptoms, without severe oesophagitis. METHODS:A total of 353 patients with symptoms of reflux oesophagitis (average age 40 years, 51% men, 33% smokers, 43% consumers of alcoholic drinks) were selected a...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1046/j.1365-2036.1998.00283.x

    authors: Poynard T,Vernisse B,Agostini H

    更新日期:1998-02-01 00:00:00

  • Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients.

    abstract:BACKGROUND:Adalimumab, at an induction dose of 160/80 mg followed by 40 mg every other week is approved for treatment of refractory Crohn's disease (CD) and for patients with loss of response to infliximab. AIM:To evaluate the indications for adalimumab, the proportion of inflammatory bowel disease patients who requir...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2008.03878.x

    authors: Swaminath A,Ullman T,Rosen M,Mayer L,Lichtiger S,Abreu MT

    更新日期:2009-02-01 00:00:00

  • Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006.

    abstract:BACKGROUND:Inflammatory bowel disease (IBD) frequently affects women during their reproductive years. Pregnancy outcome in women with IBD is well described, particularly in retrospective studies. AIM:To evaluate the pregnancy outcome in patients with IBD in a prospective European multicentre case-control study. METHO...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1365-2036.2011.04794.x

    authors: Bortoli A,Pedersen N,Duricova D,D'Inca R,Gionchetti P,Panelli MR,Ardizzone S,Sanroman AL,Gisbert JP,Arena I,Riegler G,Marrollo M,Valpiani D,Corbellini A,Segato S,Castiglione F,Munkholm P,European Crohn-Colitis Organisat

    更新日期:2011-10-01 00:00:00

  • Clinical trial: vitamin D3 treatment in Crohn's disease - a randomized double-blind placebo-controlled study.

    abstract:BACKGROUND:Vitamin D has immune-regulatory functions in experimental colitis, and low vitamin D levels are present in Crohn's disease. AIM:To assess the effectiveness of vitamin D3 treatment in Crohn's disease with regard to improved disease course. METHODS:We performed a randomized double-blind placebo-controlled tr...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2036.2010.04355.x

    authors: Jørgensen SP,Agnholt J,Glerup H,Lyhne S,Villadsen GE,Hvas CL,Bartels LE,Kelsen J,Christensen LA,Dahlerup JF

    更新日期:2010-08-01 00:00:00

  • Atrophic gastritis during long-term omeprazole therapy affects serum vitamin B12 levels.

    abstract:BACKGROUND:Omeprazole maintenance therapy for gastro-oesophageal reflux disease (GERD) has been associated with an increased incidence of atrophic gastritis in H. pylori-infected patients and with a decreased absorption of protein-bound, but not of unbound cobalamin. AIM:: To test the hypothesis that the combination o...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.1999.00616.x

    authors: Schenk BE,Kuipers EJ,Klinkenberg-Knol EC,Bloemena EC,Sandell M,Nelis GF,Snel P,Festen HP,Meuwissen SG

    更新日期:1999-10-01 00:00:00

  • Review article: safety of bismuth in the treatment of gastrointestinal diseases.

    abstract::Bismuth preparations are commonly used to treat a variety of gastrointestinal disorders, including peptic ulcers and dyspepsia. The safety profile of currently approved bismuth preparations, such as tripotassium dicitrato bismuthate (De-Nol), bismuth subsalicylate (Pepto-Bismol) and ranitidine bismuth citrate (Pylorid...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.1996.22163000.x

    authors: Tillman LA,Drake FM,Dixon JS,Wood JR

    更新日期:1996-08-01 00:00:00

  • Effects of misoprostol on healing and prevention of biopsy-induced gastroduodenal lesions occurring during the administration of diclofenac to volunteers.

    abstract:AIM:To determine whether misoprostol promotes the healing of non-steroidal anti-inflammatory drug-induced gastroduodenal lesions in a human experimental model. METHODS:Mucosal damage and healing of mucosal biopsy sites were assessed endoscopically in 10 healthy, Helicobacter pylori-negative volunteers with a normal in...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1046/j.1365-2036.1996.29171000.x

    authors: Dorta G,Nicolet M,Vouillamoz D,Margalith D,Blum AL,Armstrong D,Saraga E

    更新日期:1996-08-01 00:00:00

  • Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial.

    abstract:BACKGROUND:Health-related quality of life (HRQL) is often diminished in patients with ulcerative colitis. AIM:To evaluate the effects of vedolizumab on HRQL in patients with ulcerative colitis. METHODS:Using maintenance phase data from the GEMINI 1 study, an analysis of covariance model was used to calculate mean dif...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/apt.13852

    authors: Feagan BG,Patel H,Colombel JF,Rubin DT,James A,Mody R,Lasch K

    更新日期:2017-01-01 00:00:00

  • Antioxidant effects of aminosalicylates and potential new drugs for inflammatory bowel disease: assessment in cell-free systems and inflamed human colorectal biopsies.

    abstract:BACKGROUND:The therapeutic efficacy of 5-aminosalicylic acid in inflammatory bowel disease may be related to its antioxidant properties. AIM:To compare in vitro the antioxidant effects of conventional drugs (5-aminosalicylic acid, corticosteroids, metronidazole), with new aminosalicylates (4-aminosalicylic acid, balsa...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.1999.00484.x

    authors: Simmonds NJ,Millar AD,Blake DR,Rampton DS

    更新日期:1999-03-01 00:00:00

  • Accuracy of the stool antigen test in the diagnosis of Helicobacter pylori infection before treatment and in patients on omeprazole therapy.

    abstract:AIM:To evaluate the Helicobacter pylori stool antigen (HpSA) test in the assessment of H. pylori infection and the effect of omeprazole treatment on its accuracy. METHODS:Study 1: 140 dyspeptic patients were enrolled in the study and defined as H. pylori positive if histology and rapid urease test, or culture alone we...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.2001.00907.x

    authors: Manes G,Balzano A,Iaquinto G,Ricci C,Piccirillo MM,Giardullo N,Todisco A,Lioniello M,Vaira D

    更新日期:2001-01-01 00:00:00

  • Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B.

    abstract:AIM:To estimate the cost-effectiveness over a 4-year duration of lamivudine and adefovir dipivoxil for patients with hepatitis B 'e' antigen-negative chronic hepatitis B. METHODS:A decision analysis model has been used to perform a cost-effectiveness analysis of lamivudine and adefovir dipivoxil from the perspective o...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2006.02767.x

    authors: Buti M,Casado MA,Calleja JL,Salmerón J,Aguilar J,Rueda M,Esteban R

    更新日期:2006-02-01 00:00:00

  • The effects of propranolol on hepatic encephalopathy in patients with cirrhosis and portal hypertension.

    abstract::Beta adrenoreceptor blocking drugs have been used for the prevention of haemorrhage from oesophageal varices. However, it is possible that these agents, by virtue of their effects on hepatic blood flow, may impair liver function and precipitate hepatic encephalopathy. We have therefore studied the effect of the beta b...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1988.tb00681.x

    authors: Dunk AA,Moore J,Symon A,Dickie A,Sinclair TS,Mowat NA,Brunt PW

    更新日期:1988-04-01 00:00:00

  • Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis.

    abstract:BACKGROUND:Regulatory requirements for claims of mucosal healing in ulcerative colitis (UC) will require demonstration of both endoscopic and histologic healing. Quantifying these rates is essential for future drug development. AIMS:To meta-analyse endoscopic and histologic placebo response and remission rates in UC r...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1111/apt.14672

    authors: Ma C,Guizzetti L,Panaccione R,Fedorak RN,Pai RK,Parker CE,Nguyen TM,Khanna R,Vande Casteele N,D'Haens G,Sandborn WJ,Feagan BG,Jairath V

    更新日期:2018-06-01 00:00:00